Warhead envy: why AstraZeneca needed Spirogen
This article was originally published in Scrip
AstraZeneca's MedImmune has strengthened one of the two key pillars of its oncology platform with the acquisition of Spirogen. The deal, which sees it paying $200m up front and up to $220m linked to future milestones, brings it a potent cytotoxic agent for use in antibody-drug conjugate (ADC) development (scripintelligence.com, 15 October 2013).
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.